Ocera Therapeutics Announces Positive Results With AST-120 In Pouchitis

Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced that data from the first cohort of patients from an exploratory Phase 2 study evaluating the efficacy and safety of AST-120 in patients with active pouchitis was presented in a poster presentation at the American College of Gastroenterology Annual Scientific Meeting. [click link for full article]

More: continued here

Filed under: Clinical Trials on October 20th, 2007